0000000000525795

AUTHOR

Olof Selroos

showing 3 related works from this author

Comparing asthma treatment in elderly versus younger patients

2011

SummaryA randomised 6-month study compared two maintenance doses of budesonide/formoterol (Symbicort® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2 and 2 × 2, in 8053 asthmatics with symptoms despite treatment with inhaled corticosteroids ± inhaled long-acting β2-agonists. This analysis compared response to the two treatments in elderly patients, ≥65 years, with that in younger patients. Elderly patients with early- or late-onset asthma were also compared.Elderly patients had lower post-bronchodilator FEV1 percentage predicted normal at base…

AdultMalePulmonary and Respiratory MedicineBudesonideSymbicort SMARTmedicine.medical_specialtylaw.inventionExacerbationsElderlyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansBudesonideBudesonide/formoterolAgedAsthmaACQDose-Response Relationship Drugbusiness.industryHazard ratiomedicine.diseaseConfidence intervalAsthmaBronchodilator AgentsSurgeryTreatment OutcomeBudesonide/formoterolEthanolaminesAsthma Control QuestionnaireDisease ProgressionQuality of LifeDrug Therapy CombinationFemaleFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?

2011

Objective: Baseline inhaled corticosteroid (ICS) dose may be a factor for prescribers to consider when they select a budesonide/formoterol maintenance and reliever therapy regimen for symptomatic asthmatics. Methods: A 6-month randomized study compared two maintenance doses of budesonide/formoterol 160/4.5 µg, 1 × 2 and 2 × 2, plus as needed, in 8424 asthma patients with symptoms when treated with ICS ± an inhaled long-acting β2-agonist (LABA). In the total study population, 1339 (17%) were high-dose ICS (HD) users (≥1600 µg/day budesonide). This HD stratum was compared with the rest of the study population, divided into low-dose (LD; 400 µg/day) and medium-dose strata (MD; 401–1599 µg/day…

Pulmonary and Respiratory MedicineBudesonideAdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classSeverity of Illness Indexlaw.inventionYoung AdultRandomized controlled triallawAdrenal Cortex HormonesInternal medicineSurveys and QuestionnairesAdministration InhalationmedicineBudesonide Formoterol Fumarate Drug CombinationHumansPharmacology (medical)Anti-Asthmatic AgentsBudesonideAsthmaAgedlcsh:RC705-779Aged 80 and overDose-Response Relationship Drugbusiness.industrylcsh:Diseases of the respiratory systemMiddle Agedmedicine.diseaseAsthmaRegimenDrug CombinationsTreatment OutcomeBudesonide/formoterolAsthma Control QuestionnaireEthanolaminesAnesthesiaCorticosteroidFemaleFormoterolbusinessmedicine.drugTherapeutic advances in respiratory disease
researchProduct

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

2012

SummaryBackgroundStudies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.MethodsEuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β2-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a sm…

AdultMaleBudesonidePulmonary and Respiratory MedicineSymbicort SMARTmedicine.medical_specialtyPeak Expiratory Flow RatePropensity-matched controlsDrug Administration Schedulelaw.inventionACQ-5Budesonide/formoterol maintenance and reliever therapyPharmacotherapyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsDosingBudesonideAsthmaSmokersDose-Response Relationship Drugbusiness.industrySmokingmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionDrug Therapy CombinationFemaleFormoterol FumarateFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct